GlobalData on MSN14 小时
Candel Therapeutics stock drops despite OS improvement in PDAC trialData from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈